C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 071.3 INR -0.07% Market Closed
Market Cap: 216.7B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Net Margin
Concord Biotech Ltd

30.2%
Current
30%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.2%
=
Net Income
3.3B
/
Revenue
10.9B

Net Margin Across Competitors

Country IN
Market Cap 216.7B INR
Net Margin
30%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 372B USD
Net Margin
17%
Country US
Market Cap 257.3B USD
Net Margin
19%
Country CH
Market Cap 200.6B CHF
Net Margin
20%
Country UK
Market Cap 162.5B GBP
Net Margin
13%
Country CH
Market Cap 179.9B CHF
Net Margin
35%
Country US
Market Cap 146B USD
Net Margin
7%
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
216.7B INR
Industry
Pharmaceuticals

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

CONCORDBIO Intrinsic Value
1 110.45 INR
Overvaluation 46%
Intrinsic Value
Price
C

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.2%
=
Net Income
3.3B
/
Revenue
10.9B
What is the Net Margin of Concord Biotech Ltd?

Based on Concord Biotech Ltd's most recent financial statements, the company has Net Margin of 30.2%.